Unicycive Therapeutics (UNCY) Other Gross PP&E Adjustments (2020 - 2026)
Unicycive Therapeutics posted quarterly Other Gross PP&E Adjustments of -$707000.0 for Q1 2026, down 82.22% year-on-year from -$4.0 million in Q1 2025, and up 30.07% on a QoQ basis from -$1.0 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$707000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 82.22% year-over-year to -$707000.0; the trailing twelve-month figure through Mar 2026 stood at -$707000.0 (down 82.22% YoY), and the FY2025 full-year result was -$1.0 million, up 19.83% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$707000.0, up from -$1.0 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$111000.0 in Q3 2025 and bottomed at -$1.3 million in Q4 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$665000.0 (2024), against an average of -$624000.0.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments plunged 368.18%; it then soared 83.68% in 2025.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$496000.0 in 2022, then slumped by 132.06% to -$1.2 million in 2023, then fell by 9.56% to -$1.3 million in 2024, then advanced by 19.83% to -$1.0 million in 2025, then jumped by 30.07% to -$707000.0 in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$707000.0 (Q1 2026), -$1.0 million (Q4 2025), and -$111000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -707,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -707,000.00 |
| Mar 31, 2026 | -707,000.00 |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | -111,000.00 |
| Sep 30, 2025 | -111,000.00 |
| Jun 30, 2025 | -250,000.00 |
| Jun 30, 2025 | -250,000.00 |
| Mar 31, 2025 | -388,000.00 |
| Mar 31, 2025 | -388,000.00 |
| Dec 31, 2024 | -1.26 Mn |
| Dec 31, 2024 | -1.26 Mn |
| Sep 30, 2024 | -680,000.00 |
| Sep 30, 2024 | -680,000.00 |
| Jun 30, 2024 | -536,000.00 |
| Jun 30, 2024 | -536,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Dec 31, 2023 | -1.15 Mn |
| Dec 31, 2023 | -1.15 Mn |
| Sep 30, 2023 | -824,000.00 |
| Sep 30, 2023 | -824,000.00 |
| Jun 30, 2023 | -902,000.00 |
| Jun 30, 2023 | -902,000.00 |
| Mar 31, 2023 | -982,000.00 |
| Mar 31, 2023 | -982,000.00 |
| Dec 31, 2022 | -496,000.00 |
| Dec 31, 2022 | -496,000.00 |
| Sep 30, 2022 | -176,000.00 |
| Sep 30, 2022 | -176,000.00 |
| Jun 30, 2022 | -215,000.00 |
| Jun 30, 2022 | -215,000.00 |
| Mar 31, 2022 | -253,000.00 |
| Mar 31, 2022 | -253,000.00 |
| Dec 31, 2021 | -502,000.00 |
| Dec 31, 2021 | -502,000.00 |
| Dec 31, 2020 | -71,000.00 |
| Dec 31, 2020 | -71,000.00 |